Sidoti Research Analysts Cut Earnings Estimates for USNA

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti lowered their Q2 2026 earnings per share (EPS) estimates for USANA Health Sciences in a research report issued to clients and investors on Tuesday, April 21st. Sidoti analyst A. Lebiedzinski now anticipates that the company will earn $0.43 per share for the quarter, down from their prior forecast of $0.45. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.00 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.65 EPS and FY2026 earnings at $1.95 EPS.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The business had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million.

A number of other equities research analysts have also issued reports on the company. Zacks Research upgraded USANA Health Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

USANA Health Sciences Price Performance

Shares of USANA Health Sciences stock opened at $19.55 on Thursday. The business has a 50 day simple moving average of $18.73 and a two-hundred day simple moving average of $19.95. USANA Health Sciences has a 12 month low of $16.60 and a 12 month high of $38.32. The stock has a market capitalization of $360.87 million, a P/E ratio of 35.54, a PEG ratio of 0.81 and a beta of 0.71.

Insider Activity

In other news, insider Joshua Foukas sold 4,461 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $21.34, for a total value of $95,197.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.82% of the stock is owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of large investors have recently made changes to their positions in USNA. Nantahala Capital Management LLC purchased a new position in USANA Health Sciences in the fourth quarter worth approximately $11,485,000. Millennium Management LLC grew its position in USANA Health Sciences by 715.7% in the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock worth $5,603,000 after acquiring an additional 250,424 shares during the period. Two Sigma Investments LP grew its position in USANA Health Sciences by 349.8% in the third quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock worth $4,434,000 after acquiring an additional 125,158 shares during the period. UBS Group AG grew its position in USANA Health Sciences by 252.3% in the fourth quarter. UBS Group AG now owns 138,334 shares of the company’s stock worth $2,715,000 after acquiring an additional 99,063 shares during the period. Finally, Tudor Investment Corp ET AL grew its position in USANA Health Sciences by 354.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock worth $2,153,000 after acquiring an additional 85,570 shares during the period. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.